Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

3.22 (USD) • At close November 4, 2024
Bedrijfsnaam Xeris Biopharma Holdings, Inc.
Symbool XERS
Munteenheid USD
Prijs 3.22
Beurswaarde 479,776,780
Dividendpercentage 0%
52-weken bereik 1.46 - 3.39
Industrie Biotechnology
Sector Healthcare
CEO Mr. Paul R. Edick
Website https://www.xerispharma.com

An error occurred while fetching data.

Over Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary

Vergelijkbare Aandelen

SOPHiA GENETICS SA logo

SOPHiA GENETICS SA

SOPH

3.75 USD

Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc.

MCRB

0.807 USD

Generation Bio Co. logo

Generation Bio Co.

GBIO

2.16 USD

Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc.

PHAT

18.94 USD

Zynex, Inc. logo

Zynex, Inc.

ZYXI

8 USD

LianBio logo

LianBio

LIAN

0.319 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)